Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GED 0301 PK Study: Food, Formulation, and PPI Effect
NCT02957474Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2016
- Primary completion
- Dec 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mongersen in Crohn's disease (4 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve from time zero to infinity. Started Nov 2016; status: completed.
02
Drugs
mongersen
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02957474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02957474.